Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

H Lundbeck says treatment with once-monthly Abilify Maintena reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics


Monday, 7 Apr 2014 06:00am EDT 

H Lundbeck A/S:Says treatment with once-monthly Abilify Maintena (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics.Says in the multi-centre, open-label, North-American mirror-image study patients with schizophrenia, who had been treated with oral antipsychotics as standard of care, were switched to Abilify Maintena once-monthly 400 mg and followed for six months in a naturalistic community setting.Results from the Abilify Maintena treatment period were compared retrospectively with the treatment period on oral antipsychotics prior to the switch in the same patients and setting.The study primary endpoint showed that Abilify Maintena once-monthly 400 mg significantly reduced the rates of psychiatric hospitalisation by 10-fold during the last three months versus prior oral antipsychotic.The results were announced by the company and Otsuka Pharmaceutical Europe Ltd. 

Company Quote

128.1
2.8 +2.23%
19 Sep 2014